Carol Ashe currently serves as the Chief Business Officer for the New York Genome Center and is responsible for identifying and executing on revenue generating business development opportunities.
Ms. Ashe is an accomplished life sciences executive leader with more than 30 years of experience in corporate and business development, venture capital, and related patent and legal matters in the pharmaceutical and biotech industries. She has extensive depth and breadth of transactional expertise in negotiating and structuring transactions involving biotech and pharmaceutical companies of all stages. Previously, Ms. Ashe worked at GlaxoSmithKline where her senior roles included partner at SR One Ltd, GSK’s venture capital business, head of GSK’s US Corporate Legal department supporting US-based mergers, acquisitions and equity investments, and head of GSK’s global Business Development Transactions legal team supporting both the pharmaceutical and consumer healthcare business units. She also served as Vice President of Corporate Development for Endo’s branded, generic and platform drug delivery pharmaceutical business units. Ms. Ashe is currently a non-executive Director for Aptose Biosciences, a clinical-stage oncology company, and a member of the Board of Directors at Elicio Therapeutics, a next-generation immunotherapy company.
Ms. Ashe holds a JD from the Villanova University School of Law and a BS in Biology from the Pennsylvania State University. She is a registered patent attorney.